Aug. 31 Quick Takes: Mylan, Biocon launch cheaper insulin in U.S.; plus: AZ, bluebird, Lipocine, Amgen, AbbVie-Morphic, Polyphor-Fosun and Milestone

Mylan, Biocon launch long-acting insulin biosimilar in U.S.

Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:532523) launched Semglee insulin glargine in the U.S. at a wholesale acquisition cost (WAC) of $147.98 per package of five 3 mL pens and $98.65 per 10 mL vial, which the companies said is the lowest WAC for a marketed long-acting insulin glargine. FDA approved Semglee via the 505(b)(2) NDA pathway in June for the same indications as Lantus insulin glargine from Sanofi (Euronext:SAN; NASDAQ:SNY): controlling high glucose levels in adults with Type II diabetes and adults and children with Type I diabetes (see “Biocon, Mylan Insulin Product Could Herald Cheaper Insulin in U.S.”). ...